Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 28:4:Doc08.
doi: 10.3205/id000026. eCollection 2016.

Zincophorin - biosynthesis in Streptomyces griseus and antibiotic properties

Affiliations

Zincophorin - biosynthesis in Streptomyces griseus and antibiotic properties

Elisabeth Walther et al. GMS Infect Dis. .

Abstract

Zincophorin is a polyketide antibiotic that possesses potent activity against Gram-positive bacteria, including human pathogens. While a number of total syntheses of this highly functionalized natural product were reported since its initial discovery, the genetic basis for the biosynthesis of zincophorin has remained unclear. In this study, the co-linearity inherent to polyketide pathways was used to identify the zincophorin biosynthesis gene cluster in the genome of the natural producer Streptomyces griseus HKI 0741. Interestingly, the same locus is fully conserved in the streptomycin-producing actinomycete S. griseus IFO 13350, suggesting that the latter bacterium is also capable of zincophorin biosynthesis. Biological profiling of zincophorin revealed a dose-dependent inhibition of the Gram-positive bacterium Streptococcus pneumoniae. The antibacterial effect, however, is accompanied by cytotoxicity. Antibiotic and cytotoxic activities were completely abolished upon esterification of the carboxylic acid group in zincophorin.

Keywords: Streptococcus pneumoniae; Streptomyces griseus; antibiotic; griseochelin; polyketide; zincophorin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Table 1
Table 1. PKS assembly line for the biosynthesis of zincophorin
Table 2
Table 2. Antibacterial activity of zincophorin, daptomycin, and imipenem. Mean MIC and MBIC values in μM with standard deviation determined for three reference strains and four clinical isolates of S. pneumoniae in microtiter broth dilution and biofilm assay, respectively, are shown.
Table 3
Table 3. Cytotoxicity of zincophorin, zincophorin methyl ester, daptomycin, and imipenem. Mean values of the 50% cytotoxic concentrations in µM (CC50) with standard deviation are shown.
Figure 1
Figure 1. Structures of zincophorin (R=H) and its methyl ester (R=CH3).
Figure 2
Figure 2. (A) Organization of the zincophorin biosynthesis gene cluster. (B) Molecular assembly line deduced from zinA to zinG and proposed biosynthesis of zincophorin via the intermediate pre-zincophorin. The acyl-CoA-derived C2 and C3 building blocks are highlighted in bold. The domain notation is given in Table 1.
Figure 3
Figure 3. Dose dependence of the effect of zincophorin on growth and biofilm formation of S. pneumoniae DSM20566. Mean values of the inhibitory effect in % with standard deviation of at least 3 tests each with 2 parallels are shown.
Figure 4
Figure 4. MultAlin [51] sequence alignment of ZinJ with the epoxide hydrolases SalBIII and IdmP-Cyc from salinomycin and indanomycin biosynthesis [45], [46]. Selected amino acid residues of the active site cavity [44] are indicated with arrows.

Similar articles

Cited by

References

    1. Genilloud O. The re-emerging role of microbial natural products in antibiotic discovery. Antonie Van Leeuwenhoek. 2014 Jul;106(1):173–188. doi: 10.1007/s10482-014-0204-6. - DOI - PubMed
    1. Müller R, Wink J. Future potential for anti-infectives from bacteria – how to exploit biodiversity and genomic potential. Int J Med Microbiol. 2014 Jan;304(1):3–13. doi: 10.1016/j.ijmm.2013.09.004. - DOI - PubMed
    1. Pidot SJ, Coyne S, Kloss F, Hertweck C. Antibiotics from neglected bacterial sources. Int J Med Microbiol. 2014 Jan;304(1):14–22. doi: 10.1016/j.ijmm.2013.08.011. - DOI - PubMed
    1. Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod. 2014 Mar;77(3):703–723. doi: 10.1021/np5000796. - DOI - PubMed
    1. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013 Oct;66(10):571–591. doi: 10.1038/ja.2013.86. - DOI - PubMed

LinkOut - more resources